Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells
Condition(s):Healthy SubjectsLast Updated:April 14, 2016Terminated
Hide Studies Not Open or Pending
Condition(s):Healthy SubjectsLast Updated:April 14, 2016Terminated
Condition(s):Acute Myeloid LeukemiaLast Updated:December 7, 2016Completed
Condition(s):Schizophrenia; Schizoaffective Disorder; Bipolar DisorderLast Updated:January 27, 2009Completed
Condition(s):SchizophreniaLast Updated:November 25, 2020Terminated
Condition(s):Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Diabetes Mellitus, Type 2Last Updated:October 21, 2015Completed
Condition(s):Obesity; Weight Gain; Psychotropic Induced Weight GainLast Updated:January 2, 2019Completed
Condition(s):Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety DisordersLast Updated:February 28, 2018Terminated
Condition(s):SchizophreniaLast Updated:January 23, 2019Completed
Condition(s):Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective DisordersLast Updated:October 11, 2018Completed
Condition(s):StrokeLast Updated:August 9, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.